BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Inaba M, Mitsuhashi J, Sawada H, Miike N, Naoe Y, Daimon A, Koizumi K, Tsujimoto H, Fukushima M. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 1996;87:212-220. [PMID: 8609072 DOI: 10.1111/j.1349-7006.1996.tb03161.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Chung YM, Park. S, Park JK, Kim Y, Kang Y, Yoo YD. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Letters 2000;159:95-101. [DOI: 10.1016/s0304-3835(00)00535-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
2 Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N, Miki T. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 2001;92:510-8. [PMID: 11505394 DOI: 10.1002/1097-0142(20010801)92:3<510::aid-cncr1349>3.0.co;2-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS, Kim NS. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. 2004;214:19-33. [PMID: 15331170 DOI: 10.1016/j.canlet.2004.04.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
4 Inaba M, Tanaka T, Sawada H. Increased sensitivity to long-term 5-fluorouracil exposure of human colon cancer HT-29 cells resistant to short-term exposure. Jpn J Cancer Res 1998;89:323-7. [PMID: 9600127 DOI: 10.1111/j.1349-7006.1998.tb00565.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
5 Nakanishi H, Kobayashi K, Nishimura T, Inada K, Tsukamoto T, Tatematsu M. Chemosensitivity of micrometastases and circulating tumor cells to uracil and tegafur as evaluated using LacZ gene-tagged Lewis lung carcinoma cell. Cancer Letters 1999;142:31-41. [DOI: 10.1016/s0304-3835(99)00114-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Inaba M, Sawada H, Sadata A, Hamada H. Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction. Jpn J Cancer Res 1999;90:349-54. [PMID: 10359051 DOI: 10.1111/j.1349-7006.1999.tb00754.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
7 Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 2007;98:779-89. [PMID: 17441963 DOI: 10.1111/j.1349-7006.2007.00477.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
8 Mader RM, Müller M, Steger GG. Resistance to 5-Fluorouracil. General Pharmacology: The Vascular System 1998;31:661-6. [DOI: 10.1016/s0306-3623(98)00191-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
9 Ciccolini J, Peillard L, Aubert C, Formento P, Milano G, Catalin J. Monitoring of the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 human colon cell line: application to modulation of metabolism and cytotoxicity study. Fundam Clin Pharmacol 2000;14:147-54. [PMID: 10796062 DOI: 10.1111/j.1472-8206.2000.tb00403.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
10 Temmink OH, de Bruin M, Comijn EM, Fukushima M, Peters GJ. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. Anticancer Drugs 2005;16:285-92. [PMID: 15711180 DOI: 10.1097/00001813-200503000-00007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
11 Miyake K, Imura S, Yoshizumi T, Ikemoto T, Morine Y, Shimada M. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. Int J Clin Oncol. 2007;12:111-119. [PMID: 17443278 DOI: 10.1007/s10147-006-0634-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
12 Jiang H, Dong Q, Luo X, Shi B, Wang H, Gao H, Kong J, Zhang J, Li Z. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Cancer Lett 2014;342:113-20. [PMID: 24007863 DOI: 10.1016/j.canlet.2013.08.038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
13 Peters GJ. Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies. Ther Adv Med Oncol 2015;7:340-56. [PMID: 26557901 DOI: 10.1177/1758834015603313] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
14 Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y, Hirayama R. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 2003;89:1486-1492. [PMID: 14562021 DOI: 10.1038/sj.bjc.6601335] [Cited by in Crossref: 92] [Cited by in F6Publishing: 76] [Article Influence: 5.1] [Reference Citation Analysis]
15 Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer. 2001;37:1681-1687. [PMID: 11527696 DOI: 10.1016/S0959-8049(01)00174-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
16 Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev 2015;41:777-83. [PMID: 26428513 DOI: 10.1016/j.ctrv.2015.06.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 44] [Article Influence: 10.7] [Reference Citation Analysis]
17 Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005;5:226-243. [PMID: 16041392 DOI: 10.1038/sj.tpj.6500320] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
18 Matsuoka K, Nakagawa F, Kobunai T, Takechi T. Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression. Oncotarget 2018;9:13438-50. [PMID: 29568368 DOI: 10.18632/oncotarget.24412] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
19 Sasaki E, Tominaga K, Kuwamura H, Watanabe T, Fujiwara Y, Oshitani N, Higuchi K, Arakawa T. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism. J Gastroenterol 2007;42:816-22. [PMID: 17940834 DOI: 10.1007/s00535-007-2101-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
20 Li LH, Dong H, Zhao F, Tang J, Chen X, Ding J, Men HT, Luo WX, Du Y, Ge J, Tan BX, Cao D, Liu JY. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil. Eur J Cancer 2013;49:1752-60. [PMID: 23313143 DOI: 10.1016/j.ejca.2012.12.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
21 Dan S, Shirakawa M, Mukai Y, Yoshida Y, Yamazaki K, Kawaguchi T, Matsuura M, Nakamura Y, Yamori T. Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines. Cancer Sci 2003;94:1074-82. [PMID: 14662023 DOI: 10.1111/j.1349-7006.2003.tb01403.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
22 Tokunaga Y, Sasaki H, Saito T. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery. 2007;141:346-353. [PMID: 17349846 DOI: 10.1016/j.surg.2006.06.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
23 Ishizone S, Maruta F, Saito H, Koide N, Sugiyama A, Nakayama J, Miyagawa S. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy. 2006;52:301-307. [PMID: 17008790 DOI: 10.1159/000096002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
24 Lin AY, Hsueh JH, Hong PKA. Removal of antineoplastic drugs cyclophosphamide, ifosfamide, and 5-fluorouracil and a vasodilator drug pentoxifylline from wastewaters by ozonation. Environ Sci Pollut Res 2015;22:508-15. [DOI: 10.1007/s11356-014-3288-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 4.9] [Reference Citation Analysis]
25 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
26 Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer. 2002;38:167-176. [PMID: 11750847 DOI: 10.1016/s0959-8049(01)00339-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
27 Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M, Tatematsu M. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998;82:70-7. [DOI: 10.1002/(sici)1097-0142(19980101)82:1<70::aid-cncr8>3.0.co;2-o] [Cited by in Crossref: 93] [Article Influence: 4.0] [Reference Citation Analysis]
28 Fanciullino R, Giacometti S, Aubert C, Fina F, Martin PM, Piccerelle P, Ciccolini J. Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study. Pharm Res 2005;22:2051-7. [PMID: 16222443 DOI: 10.1007/s11095-005-8355-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
29 Yasumatsu R, Nakashima T, Komune S. Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-Fluorouracil in head and neck squamous cell carcinoma in vitro. J Oncol 2012;2012:649605. [PMID: 22545049 DOI: 10.1155/2012/649605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
30 Takechi T, Koizumi K, Tsujimoto H, Fukushima M. Screening of differentially expressed genes in 5-fluorouracil-resistant human gastrointestinal tumor cells. Jpn J Cancer Res 2001;92:696-703. [PMID: 11429060 DOI: 10.1111/j.1349-7006.2001.tb01150.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
31 Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN, Miki T. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer. 2004;100:723-731. [PMID: 14770427 DOI: 10.1002/cncr.11955] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
32 Yoshitomi I, Kawasaki G, Yanamoto S, Mizuno A. Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the dihydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil. Oral Oncol 2006;42:880-7. [PMID: 16757204 DOI: 10.1016/j.oraloncology.2005.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
33 Mader RM, Sieder AE, Braun J, Rizovski B, Kalipciyan M, Mueller MW, Jakesz R, Rainer H, Steger GG. Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro. Biochem Pharmacol. 1997;54:1233-1242. [PMID: 9416974 DOI: 10.1016/s0006-2952(97)00330-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
34 Taddia L, D'Arca D, Ferrari S, Marraccini C, Severi L, Ponterini G, Assaraf YG, Marverti G, Costi MP. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resist Updat. 2015;23:20-54. [PMID: 26690339 DOI: 10.1016/j.drup.2015.10.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
35 Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y, Hirayama R. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927-1933. [PMID: 16736497 DOI: 10.1002/ijc.22080] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
36 Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M, Ando T, Murata Y, Sasaki H, Takami K, Yamamura A, Shibata C, Sasaki I. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 2009;100:903-13. [PMID: 19302291 DOI: 10.1111/j.1349-7006.2009.01112.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
37 Mizutani Y, Wada H, Yoshida O, Fukushima M, Kawauchi A, Nakao M, Miki T. The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma. Cancer 2003;98:730-6. [PMID: 12910516 DOI: 10.1002/cncr.11570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
38 Hidaka S, Yasutake T, Fukushima M, Yano H, Haseba M, Tsuji T, Sawai T, Yamaguchi H, Nakagoe T, Ayabe H, Tagawa Y. Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells. Eur J Cancer 2003;39:975-80. [PMID: 12706367 DOI: 10.1016/s0959-8049(03)00028-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
39 Mizutani Y, Wada H, Yoshida O, Fukushima M, Kamoi K, Miki T. Prognostic significance of thymidine kinase activity in bladder carcinoma. Cancer 2002;95:2120-5. [DOI: 10.1002/cncr.10948] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]